Key result
Dazoxiben 100 mg significantly reduced plasma thromboxane levels and increased atrial pacing time to angina from 245 to 308 seconds (P<0.01) without adverse haemodynamic effects.
Why the study?
Does dazoxiben reduce transcardiac thromboxane levels and improve pacing time to angina in patients with coronary heart disease?
Does dazoxiben reduce transcardiac thromboxane levels and improve pacing time to angina in patients with coronary heart disease?
Absolute Event Rate: 308% vs 245%
p-value: p=<0.01
Dazoxiben reduces plasma thromboxane levels and increases pacing time to angina without adverse haemodynamic effects in patients with coronary heart disease.
May support thromboxane inhibition for angina threshold; leaves open need for RCTs before any practice change.
1 Plasma thromboxane levels were obtained from both the coronary sinus and aorta in patients with stable angina pectoris paced to angina, and in unstable angina patients before and after dazoxiben 100 mg. 2 Although there was a wide range of values in the different groups, dazoxiben significantly reduced plasma thromboxane levels in all patients. 3 Dazoxiben had no adverse effect on coronary and systemic haemodynamics, and atrial pacing time to angina was increased from 245 +/- 41 to 308 +/- 48s (P less than 0.01).
No takes yet. Share an insight, caveat, or question.
Hutton et al. (1983) studied Coronary heart disease (stable and unstable angina). Dazoxiben vs. Baseline (before dazoxiben) was evaluated on Atrial pacing time to angina (seconds) (p=<0.01). Dazoxiben 100 mg significantly reduced plasma thromboxane levels and increased atrial pacing time to angina from 245 to 308 seconds (P<0.01) without adverse haemodynamic effects.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: